The estimated Net Worth of Owen B. Wallace is at least $2.74 Milion dollars as of 14 September 2020. Owen Wallace owns over 6,350 units of Fulcrum Therapeutics Inc stock worth over $1,180,926 and over the last 5 years he sold FULC stock worth over $0. In addition, he makes $1,559,520 as Chief Scientific Officer at Fulcrum Therapeutics Inc.
Sign up
Owen Wallace FULC stock SEC Form 4 insiders trading
Owen has made over 7 trades of the Fulcrum Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 6,350 units of FULC stock worth $49,784 on 14 September 2020.
The largest trade he's ever made was exercising 6,350 units of Fulcrum Therapeutics Inc stock on 14 September 2020 worth over $49,784. On average, Owen trades about 2,069 units every 23 days since 2019. As of 14 September 2020 he still owns at least 133,438 units of Fulcrum Therapeutics Inc stock.
You can see the complete history of Owen Wallace stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Owen Wallace biography
Dr. Owen B. Wallace Ph.D. serves as Chief Scientific Officer of the Company.D serves has served as our chief scientific officer since April 2017. Dr. Wallace previously served as head, global discovery chemistry at Novartis Institutes for BioMedical Research, or NIBR, a pharmaceutical company, from May 2013 to April 2017. Prior to joining NIBR, he held various positions at Eli Lilly & Company, a pharmaceutical company, including site scientific leader and group senior director from July 2010 to June 2013, senior director, discovery chemistry from August 2009 to July 2010, director, discovery chemistry from December 2005 to August 2009 and head, discovery chemistry research from February 2002 to December 2005. Prior to that, Dr. Wallace was a senior research investigator at Bristol-Myers Squibb, a biopharmaceutical company, from March 1995 to May 2000. Dr. Wallace received his Ph.D. in Organic Chemistry from Yale University and his B.Sc. (Hons) in Chemistry from University College Cork in Ireland.
What is the salary of Owen Wallace?
As the Chief Scientific Officer of Fulcrum Therapeutics Inc, the total compensation of Owen Wallace at Fulcrum Therapeutics Inc is $1,559,520. There are 1 executives at Fulcrum Therapeutics Inc getting paid more, with Robert Gould having the highest compensation of $3,889,350.
How old is Owen Wallace?
Owen Wallace is 51, he's been the Chief Scientific Officer of Fulcrum Therapeutics Inc since 2017. There are 10 older and 4 younger executives at Fulcrum Therapeutics Inc. The oldest executive at Fulcrum Therapeutics Inc is Mark J. Levin, 71, who is the Exec. Chairman.
What's Owen Wallace's mailing address?
Owen's mailing address filed with the SEC is C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139.
Insiders trading at Fulcrum Therapeutics Inc
Over the last 5 years, insiders at Fulcrum Therapeutics Inc have traded over $1,450,584 worth of Fulcrum Therapeutics Inc stock and bought 5,263,802 units worth $50,137,344 . The most active insiders traders include Sanofi, Plc Gsk a Capital Management, L.P.Ra .... On average, Fulcrum Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $868,035. The most recent stock trade was executed by Alex Sapir on 3 July 2024, trading 150,000 units of FULC stock currently worth $490,500.
What does Fulcrum Therapeutics Inc do?
what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng
What does Fulcrum Therapeutics Inc's logo look like?
Complete history of Owen Wallace stock trades at Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc executives and stock owners
Fulcrum Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Robert Gould,
President, Chief Executive Officer, Director -
Owen Wallace,
Chief Scientific Officer -
Bryan Stuart,
Chief Operating Officer -
Dr. Judith A. Dunn Ph.D.,
Pres of R&D and Interim Chief Medical Officer -
Bryan E. Stuart,
Pres, CEO & Director -
Diego Cadavid,
Senior Vice President - Clinical Development -
james Geraghty,
Independent Director -
Kate Haviland,
Independent Director -
Alan Ezekowitz,
Independent Director -
James Collins,
Independent Director -
Curtis G. Oltmans J.D.,
Sr. VP, Gen. Counsel & Corp. Sec. -
Mark J. Levin,
Exec. Chairman -
Mark Levin,
Independent Chairman of the Board -
Christina Tartaglia,
IR Contact Officer -
Katina Dorton,
Independent Director -
Christi Waarich,
Director of Corp. Communications & Investor Relations -
Gregory Tourangeau,
Controller & Principal Accounting Officer -
Esther P. Rajavelu,
CFO & Treasurer -
Nicole T. Gallagher,
Director of Admin. -
Peter G. Thomson,
VP of Fin. & Accounting -
Dr. Danny Reinberg,
Founder -
Prof. Jeannie T. Lee M.D., Ph.D.,
Founder -
Dr. Rudolf Jaenisch M.D., Ph.D.,
Founder -
Dr. Michael R. Green,
Founder -
Dr. Bradley E. Bernstein M.D., Ph.D.,
Founder -
Sonja Banks,
-
Colin Hill,
-
Sanofi,
10% owner -
Rock Ventures Iii, L.P.Thir...,
-
Dimensions Capital, L.P. 6,
10% owner -
32 Fund 2, Lp Section 32 Gp...,
-
Capital, Llc Casdin Partner...,
-
Rock Ventures Iv, L.P.Third...,
-
Plc Gsk,
-
Curtis Gale Oltmans,
Chief Legal Officer -
Peter G. Thomson,
VP Finance & Accounting -
Christopher Morabito,
Chief Medical Officer -
Christopher Moxham,
Chief Scientific Officer -
Judith Dunn,
See Remarks -
Greg Tourangeau,
Principal Accounting Officer -
Esther Rajavelu,
Chief Financial Officer -
Rock Ventures Iii, L.P.Thir...,
-
Alex Sapir,
See Remarks -
Patrick Taylor Horn,
Chief Medical Officer -
Melvin H. Iii Hayes,
Chief Operating Officer -
Santiago Arroyo,
Chief Medical Officer -
Capital Management, L.P.Ra ...,
-
Alan A Musso,
Chief Financial Officer